Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Dermatitis
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Dermatitis
    TopAbstracts in Dermatitis 10/26/2009 - (DGNews)
    TopAbstracts in Dermatitis 10/12/2009 - (DGNews)
    TopAbstracts in Dermatitis 09/28/2009 - (DGNews)
    TopAbstracts in Dermatitis 09/14/2009 - (DGNews)
    TopAbstracts in Dermatitis 08/31/2009 - (DGNews)

    News archive

     Recent webcasts/CME - Dermatitis
    • Achieving Clinical Response and Improving Quality of Life With TNF-Alpha Antagonists in Patients With Psoriasis
    • A Practical Approach to Optimising Psoriasis Treatment With Anti-TNF-Alpha Monoclonal Antibodies
    • Achieving Long-Term Efficacy and Safety in Psoriasis Treatment With Anti-TNF-Alpha Agents
    • Current Perspectives in Treating Atopic Dermatitis

      Webcasts/CME archive

       Recent cases - Dermatitis
        Anaphylactic Reaction to Camomile Tea
        Severe Cutaneous Toxicity Following Treatment with Radiotherapy and Cetuximab: A Case Report
        Chronic Vulvocrural Dermatitis with Burning and Itching
        Patch Test Triggering Recurrence of Distant Dermatitis: The Flare-Up Phenomenon
        Infective Endocarditis Caused by Staphylococcus Aureus in a Patient with Atopic Dermatitis: A Case Report

        Cases archive
          




        my personal edition > dermatitis > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Childhood Atopic Eczema Responds Equally To Potent Or Mild Therapy

        A DGReview of :"Randomised controlled trial of short bursts of a potent topical corticosteroid versus prolonged use of a mild preparation for children with mild or moderate atopic eczema"
        British Medical Journal (BMJ)

        04/01/2002
        By Harvey McConnell


        A short burst of a potent topical corticosteroid is as effective and safe as prolonged use of a weak preparation for treatment of mild or moderate atopic eczema in children.

        The type of preparation is immaterial provided that the dosage is adequate, according to clinicians at the Center of Evidence Based Dermatology, Queen's Medical Center, Nottingham, England, following a randomized, double blind, parallel group 18 week study.

        Clinicians enrolled 174 children with mild or moderate atopic eczema recruited from 13 family practices and 33 children from the outpatient clinic at a teaching hospital in Nottingham.

        Atopic eczema, or atopic dermatitis affects around 15 percent of British school children and usually follows a chronic relapsing course, the clinicians point out. Topical corticosteroids have been the mainstay of treatment four decades, yet few clinical trials have studied their optimum use.

        Doctors and patients are concerned about the known side effects from the corticosteroids, including thinning of the skin. This is often the main reason for poor compliance with treatment.

        This study aimed to determine whether a three day burst of a potent topical corticosteroid was more effective than a mild preparation used continuously for seven days, without causing an increase in thinning of the skin. Children between the ages of one and 15 with atopic eczema as defined by Hanifin and Rajka's modified diagnostic criteria were enrolled. The subjects exhibited mild or moderate atopic eczema within the past month. but those with severe eczema were excluded on ethical grounds.

        The children were given either 0.1% betamethasone valerate applied for three days followed by the base ointment for four days, or 1% hydrocortisone applied for seven days. Primary outcomes were total number of scratch-free days and number of relapses.

        The clinicians found no differences between the two groups. Median number of scratch-free days was 118.0 for the mild treatment group and 117.5 for the potent treatment group. Both groups demonstrated clinically important improvements in the severity of the disease and their equality of life, and the number of relapses was small.

        They conclude: "The liberal use of an emollient might achieve similar control to topical steroids for children with mild or moderate eczema. Researchers should consider a treatment arm of emollient only for trials based in primary care."
        BMJ 2002;324:768. "Randomised controlled trial of short bursts of a potent topical corticosteroid versus prolonged use of a mild preparation for children with mild or moderate atopic eczema"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send